Reference
Pizzuti AG, et al. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients. Infectious Diseases and Therapy : 21 Oct 2020. Available from: URL: http://dx.doi.org/10.1007/s40121-020-00347-w
Rights and permissions
About this article
Cite this article
Dalbavancin vs SOC for acute bacterial skin and skin structure infections. PharmacoEcon Outcomes News 865, 9 (2020). https://doi.org/10.1007/s40274-020-7233-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7233-3